Online inquiry

IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12872MR)

This product GTTS-WQ12872MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TLR2 gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001318787.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7097
UniProt ID O60603
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12872MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2609MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ6950MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ESBA-1008
GTTS-WQ6100MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ7185MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ1128MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ14350MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG7716(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG7716
GTTS-WQ15258MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ10499MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY3002813
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW